Prevalence of HIV drug-resistance mutations in HIV-infected Mexican patients heavily experienced to antiretroviral therapy

@inproceedings{GaytnMartnez2010PrevalenceOH,
  title={Prevalence of HIV drug-resistance mutations in HIV-infected Mexican patients heavily experienced to antiretroviral therapy},
  author={JE Gayt{\'a}n-Mart{\'i}nez and JA Mata-Mar{\'i}n and Fernanda Guti{\'e}rrez-Escolano and Leticia M P{\'e}rez-Saleme and Sandra Trevi{\~n}o-P{\'e}rez and JG V{\'a}zquez-Rosales and N Mat{\'i}as-Juan and RD D{\'i}az-Ramos and Rafael Arias-Flores},
  year={2010}
}
Results We assessed 178 subjects, mean age (SD ±) of our subjects was 41.9 ± 11.9; 91% where male, who failed 2 to 15 ART regimen (median 5). CDC status was A 20%, B 21% and C 59%; 4% were coinfected with HBV and 2% were infected with HCV. Month median drug exposure was 121 (range 12-219). Ninety nine (55.6%) had triple class drug mutations, 170 (95.5%) had NRTI mutations, 113 (63.5%) had NNRTI mutations and 173 (97.2%) had PIs mutations. The most frequent NRTI mutation belonged to TAM pathways… CONTINUE READING